The aim of the study was to characterize the expression of GLUT5 in healthy colon mucosa and colon cancer tissue, as well as to assess whether GLUT5 inhibitor, N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA), might decrease the viability of colon cancer cells in vitro. Here, SLC2A5 is linked to malignant colon neoplasm.